DK1361884T3 - Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus - Google Patents

Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus

Info

Publication number: DK1361884T3
Authority: DK; Denmark
Prior art keywords: neovlastic; reovirus; sensitization; chemotherapeutic agent; cells resistant
Prior art date: 2001-02-20

Application number

DK02701122.0T

Other languages

English (en)

Inventor

Matthew C Coffey

Bradley G Thompson

Original Assignee

Oncolytics Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-20

Filing date

2002-02-19

Publication date

2011-10-03

2002-02-19 Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc

2011-10-03 Application granted granted Critical

2011-10-03 Publication of DK1361884T3 publication Critical patent/DK1361884T3/da

Links

241000702263 Reovirus sp. Species 0.000 title 1
206010070834 Sensitisation Diseases 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
229940127089 cytotoxic agent Drugs 0.000 title 1
230000008313 sensitization Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Virology (AREA)
Hematology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Oncology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK02701122.0T 2001-02-20 2002-02-19 Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus DK1361884T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27036301P	2001-02-20	2001-02-20
PCT/CA2002/000201 WO2002066040A2 (en)	2001-02-20	2002-02-19	Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus

Publications (1)

Publication Number	Publication Date
DK1361884T3 true DK1361884T3 (da)	2011-10-03

Family

ID=23031034

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02701122.0T DK1361884T3 (da)	2001-02-20	2002-02-19	Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus

Country Status (15)

Country	Link
US (5)	US7264798B2 (da)
EP (2)	EP2314301A3 (da)
JP (3)	JP4951194B2 (da)
AR (1)	AR035227A1 (da)
AT (1)	ATE516807T1 (da)
AU (2)	AU2002234453B2 (da)
BR (1)	BR0207691A (da)
CA (1)	CA2437468C (da)
DK (1)	DK1361884T3 (da)
ES (1)	ES2367768T3 (da)
IL (2)	IL157167A0 (da)
MX (1)	MXPA03007486A (da)
NZ (2)	NZ537709A (da)
WO (1)	WO2002066040A2 (da)
ZA (1)	ZA200305875B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6110461A (en) *	1997-08-13	2000-08-29	Oncolytics Biotech Inc.	Reovirus for the treatment of neoplasia
US6136307A (en)	1997-08-13	2000-10-24	Oncolytics Biotech Inc.	Reovirus for the treatment of cellular proliferative disorders
AR035227A1 (es) *	2001-02-20	2004-05-05	Oncolytics Biotech Inc	Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
PT1505993E (pt) *	2002-05-10	2012-05-15	Oncolytics Biotech Inc	Sensibilização de células neoplásicas a terapia de radiação com vírus oncolíticos
WO2004096126A2 (en) *	2003-04-25	2004-11-11	Wellstat Biologics Corporation	Treating hepatocellular carcinomas using therapeutic viruses
WO2005047458A2 (en)	2003-06-18	2005-05-26	Genelux Corporation	Modified recombinant vaccina viruses and other microorganisms, uses thereof
CN1946421B (zh)	2004-04-27	2013-07-17	威尔斯达特生物制剂公司	使用病毒和喜树碱进行的癌症治疗
WO2005112966A1 (en) *	2004-05-21	2005-12-01	Orison Biotechnology Inc.	Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject
NZ562951A (en) *	2005-07-14	2011-09-30	Wellstat Biologics Corp	Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination
US10668119B2 (en)	2005-08-01	2020-06-02	Virocure, Inc.	Attenuated reovirus
WO2007099401A2 (en) *	2005-08-01	2007-09-07	University Technologies International, Inc.	Oncolytic attenuated reoviruses for treatment of proliferative disorders
PT1951274E (pt) *	2005-11-24	2009-12-14	Aicuris Gmbh & Co Kg	Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
WO2008100292A2 (en)	2006-10-16	2008-08-21	Genelux Corporation	Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
US10369171B2 (en)	2007-03-13	2019-08-06	Virocure, Inc.	Attenuated reoviruses for selection of cell populations
WO2008150496A2 (en) *	2007-05-31	2008-12-11	Genelux Corporation	Assay for sensitivity to chemotherapeutic agents
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20100260832A1 (en) *	2007-06-27	2010-10-14	Poniard Pharmaceuticals, Inc.	Combination therapy for ovarian cancer
EP2173368A1 (en) *	2007-07-18	2010-04-14	Genelux Corporation	Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2211880A4 (en) *	2007-10-22	2012-11-14	Oncolytics Biotech Inc	TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES
EP2249644A4 (en) *	2008-02-08	2012-05-30	Poniard Pharmaceuticals Inc	PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER
EP2300023A2 (en) *	2008-05-16	2011-03-30	Genelux Corporation	Microorganisms for preventing and treating neoplasms accompanying cellular therapy
CN102124335B (zh) *	2008-05-22	2014-07-30	第一药品株式会社	基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
TW200951143A (en) *	2008-05-27	2009-12-16	Oncolytics Biotech Inc	Modulating interstitial pressure and oncolytic viral delivery and distribution
US8470312B2 (en) *	2008-05-27	2013-06-25	Oncolytics Biotech, Inc.	Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2013163724A1 (en) *	2012-04-30	2013-11-07	Oncolytics Biotech Inc.	Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
WO2016065330A1 (en)	2014-10-24	2016-04-28	Aladar Szalay	Combination immunotherapy approach for treatment of cancer
CN104881181B (zh) *	2015-05-27	2019-07-26	联想(北京)有限公司	显示方法及电子设备
CN113271955A (zh)	2018-11-06	2021-08-17	卡利迪生物治疗有限公司	用于细胞介导的溶瘤病毒疗法的增强的系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0931830T3 (da)	1993-02-16	2001-06-11	Onyx Pharma Inc	Cytopatiske vira til terapi og profylakse af neoplasi
PT696326E (pt)	1993-04-30	2003-08-29	Wellstat Biologics Corp	Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
US5776743A (en)	1994-09-06	1998-07-07	La Jolla Cancer Research Foundation	Method of sensitizing tumor cells with adenovirus E1A
US6136307A (en)	1997-08-13	2000-10-24	Oncolytics Biotech Inc.	Reovirus for the treatment of cellular proliferative disorders
US6110461A (en)	1997-08-13	2000-08-29	Oncolytics Biotech Inc.	Reovirus for the treatment of neoplasia
US6565831B1 (en) *	1999-02-24	2003-05-20	Oncolytics Biotech Inc.	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
NZ503664A (en)	1997-10-09	2002-08-28	Pro Virus Inc	A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
US6428968B1 (en) *	1999-03-15	2002-08-06	The Trustees Of The University Of Pennsylvania	Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CA2720361A1 (en) *	1999-11-12	2001-05-25	Oncolytics Biotech, Inc.	Viruses for the treatment of cellular proliferative disorders
AR035227A1 (es) *	2001-02-20	2004-05-05	Oncolytics Biotech Inc	Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7163678B2 (en) *	2002-11-07	2007-01-16	Oncolytics Biotech Inc.	Reovirus for the treatment of ral-mediated cellular proliferative disorders

2002
- 2002-02-12 AR ARP020100466A patent/AR035227A1/es unknown
- 2002-02-15 US US10/076,074 patent/US7264798B2/en not_active Expired - Lifetime
- 2002-02-19 BR BR0207691-8A patent/BR0207691A/pt not_active IP Right Cessation
- 2002-02-19 EP EP10013901A patent/EP2314301A3/en not_active Withdrawn
- 2002-02-19 CA CA002437468A patent/CA2437468C/en not_active Expired - Lifetime
- 2002-02-19 NZ NZ537709A patent/NZ537709A/en unknown
- 2002-02-19 WO PCT/CA2002/000201 patent/WO2002066040A2/en not_active Ceased
- 2002-02-19 MX MXPA03007486A patent/MXPA03007486A/es active IP Right Grant
- 2002-02-19 IL IL15716702A patent/IL157167A0/xx unknown
- 2002-02-19 ES ES02701122T patent/ES2367768T3/es not_active Expired - Lifetime
- 2002-02-19 EP EP02701122A patent/EP1361884B1/en not_active Expired - Lifetime
- 2002-02-19 AU AU2002234453A patent/AU2002234453B2/en not_active Expired
- 2002-02-19 AT AT02701122T patent/ATE516807T1/de not_active IP Right Cessation
- 2002-02-19 JP JP2002565598A patent/JP4951194B2/ja not_active Expired - Lifetime
- 2002-02-19 DK DK02701122.0T patent/DK1361884T3/da active
- 2002-02-19 NZ NZ527399A patent/NZ527399A/en unknown
2003
- 2003-07-30 IL IL157167A patent/IL157167A/en active IP Right Grant
- 2003-07-30 ZA ZA200305875A patent/ZA200305875B/en unknown
2007
- 2007-05-31 US US11/809,293 patent/US7608257B2/en not_active Expired - Lifetime
- 2007-08-16 AU AU2007207860A patent/AU2007207860B2/en not_active Expired
2008
- 2008-02-18 JP JP2008036723A patent/JP2008120837A/ja not_active Withdrawn
2009
- 2009-09-08 US US12/555,453 patent/US7964187B2/en not_active Expired - Fee Related
2011
- 2011-05-17 US US13/109,631 patent/US20110243890A1/en not_active Abandoned
2012
- 2012-01-13 JP JP2012005027A patent/JP2012072192A/ja active Pending
- 2012-09-24 US US13/625,259 patent/US8658158B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8658158B2 (en)	2014-02-25
US7964187B2 (en)	2011-06-21
IL157167A0 (en)	2004-02-08
CA2437468A1 (en)	2002-08-29
WO2002066040A3 (en)	2003-05-30
EP2314301A3 (en)	2011-08-17
CA2437468C (en)	2007-06-19
ZA200305875B (en)	2004-07-30
AR035227A1 (es)	2004-05-05
US7264798B2 (en)	2007-09-04
HK1060520A1 (en)	2004-08-13
US20020168344A1 (en)	2002-11-14
AU2002234453B2 (en)	2007-05-17
JP4951194B2 (ja)	2012-06-13
US20130017172A1 (en)	2013-01-17
EP1361884A2 (en)	2003-11-19
US7608257B2 (en)	2009-10-27
AU2007207860B2 (en)	2008-10-23
US20080031851A1 (en)	2008-02-07
US20100021432A1 (en)	2010-01-28
AU2007207860A1 (en)	2007-09-06
ATE516807T1 (de)	2011-08-15
US20110243890A1 (en)	2011-10-06
JP2004517966A (ja)	2004-06-17
NZ527399A (en)	2005-09-30
ES2367768T3 (es)	2011-11-08
IL157167A (en)	2014-05-28
EP1361884B1 (en)	2011-07-20
MXPA03007486A (es)	2003-12-08
JP2008120837A (ja)	2008-05-29
JP2012072192A (ja)	2012-04-12
NZ537709A (en)	2006-11-30
WO2002066040A2 (en)	2002-08-29
WO2002066040A8 (en)	2003-03-20
EP2314301A2 (en)	2011-04-27
BR0207691A (pt)	2006-01-31

Publication	Publication Date	Title
MXPA03007486A (es)	2003-12-08	Sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus.
DK1386921T3 (da)	2009-03-23	Mellemprodukter til fremstilling af anti-trombotiske 4H-cycolopenta-1,3-dioxol-derivater
LTPA2014013I1 (lt)	2014-04-25	Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai
LU93311I2 (fr)	2017-01-26	Mancozèbe, valifenalate
DK3138566T3 (da)	2022-01-31	Behandling af phenylketonuri med bh4
DK1360287T4 (da)	2019-06-11	Fremgangsmåder til modifikation af eukaryotiske celler
DK1633726T3 (da)	2011-03-28	Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
DE60234409D1 (de)	2009-12-31	Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung
DK1339679T3 (da)	2005-12-12	3-Aroylindolderivater og deres anvendelse som agonister af CB2-receptorer
NO20013463D0 (no)	2001-07-12	<omega>-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
PT1362050E (pt)	2005-05-31	Derivados de pirimidina para inibicao de proliferacao celular
DK1373722T3 (da)	2008-10-20	Overvågning af tårnsvingning
NO20034930D0 (no)	2003-11-05	Substituerte cykloheksan-1,4-diaminderivater
IS5640A (is)	2000-09-26	Ný kristalla form af Bensímídazól efnasambandi gegn veirum
DK1212320T3 (da)	2005-08-08	Phenylpiperazinderivater som inhibitorer for genoptag af serotonin
DK1170288T3 (da)	2004-11-29	Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK1776136T3 (da)	2012-12-03	Behandling af tilstande, der involverer demyelinisering
DK1066029T3 (da)	2003-01-27	Suspension af peroralt aktivt middel
DK1499729T5 (da)	2011-12-05	Derivater af det NF-kappab-inducerende enzym, fremstilling og anvendelse deraf
DE60309977D1 (de)	2007-01-11	Korrekturschaltung, Verzögerungsschaltung und Ringoszillator
DK1505993T3 (da)	2012-05-21	Sensibilisering af neoplastiske celler for stråleterapi med onkolytiske vira
NO20052663D0 (no)	2005-06-03	Partikkel med langstrakt form, anvendelse derav som en katalysator eller baerer
DK1827427T3 (da)	2008-11-24	Aryloxyethylaminderivater med en kombination af partiel dopamin-D2 receptoragonisme og inhibition af genoptag af serotonin
DK1147119T3 (da)	2004-01-19	2,3-O-isopropylidenderivater af monosaccharider som celleadhæsionsinhibitorer
NO20041999L (no)	2004-05-14	Viral inhibering med n-docosanol